Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.32 |
| ▸ | MLNR | O43193 | 2/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12655673 | 0.94 | FFAR4 (0.34) | GPR6NAAAFFAR4MLNRKCNH2 | |
| SCHEMBL862857 | 0.94 | FFAR4 (0.34) | GPR6NAAAFFAR4MLNRKCNH2 | |
| SCHEMBL862830 | 0.92 | ALDH1A1 (0.34) | GPR6NAAAFFAR4P2RX3P2RX7 | |
| SCHEMBL862252 | 0.90 | SCN9A (0.38) | GPR6NAAAP2RX3 | |
| SCHEMBL862471 | 0.84 | SCN9A (0.38) | GPR6 | |
| SCHEMBL12674113 | 0.83 | CYP2C8 (0.40) | KCNK3 | |
| SCHEMBL832326 | 0.77 | GPR6 (0.37) | GPR6NAAAFFAR4P2RX3P2RX7 | |
| SCHEMBL3693520 | 0.77 | GPR6 (0.37) | GPR6NAAAFFAR4P2RX3P2RX7 | |
| SCHEMBL12674114 | 0.77 | CYP2C8 (0.40) | — | |
| SCHEMBL12665694 | 0.76 | FABP4 (0.41) | GPR6P2RX3P2RX7ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | GPR6 2012/4885NAAA 822/4885FFAR4 4134/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | GPR6 3272/4885NAAA 1465/4885FFAR4 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.